Latest
industry research report on: Global Breast Cancer Market | Industry
Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth,
Segmentation, Parameters, Forecasts
The breast cancer
pipeline is the largest in the pharmaceutical industry, with 1,050
products in active development across all stages. The range of
mechanisms of action employed by these compounds is also highly diverse,
especially in comparison to the existing market landscape. The degree
and proportion of breakthrough innovations in this pipeline is
exceptional & GBI Research analysis identified 333 first-in-class
programs in the breast cancer pipeline, acting on 251 first-in-class
molecular targets. This accounts for some 39% of all products with a
disclosed molecular target, and is reflective of the high degree of
innovation in this indication. This has far-reaching strategic
implications for all market participants, as despite the high attrition
rate in breast cancer, it is highly likely many of the first-in-class
products will reach the market over the coming decade and, will have the
opportunity to transform the clinical and commercial landscape.
Potential
driving factors behind this market include a very large and growing
patient pool, a well-established disease market with a number of strong
unmet needs, and the strong understanding of the disease pathophysiology
that has developed over the last decade, facilitating the development
of novel compounds that may fill the unmet needs.
Some
289 first-in-class products that are currently in development have not
yet been involved in licensing or co-development deals, meaning there
are numerous opportunities for in-licensing or co-development in this
indication, which already has a strong track record of breakthrough
innovation yielding highly commercially and clinically successful
therapies.
Scope
- The report analyzes innovation in breast cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products in breast cancer, and pinpoints opportunities for in-licensing.
- A brief introduction to breast cancer, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
- The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
- Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
- Assessment of the licensing and co-development deal landscape for breast cancer therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.
Reasons to buy
- Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
- Visualize the composition of the breast cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
- Analyze the breast cancer pipeline, stratified by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals, and producing a list of breast cancer therapies that are not yet involved in deals and may be potential investment opportunities.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time
and money for our clients. We are a one stop solution for all your
research needs, our main offerings are syndicated research reports,
custom research, subscription access and consulting services. We serve
all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
No comments:
Post a Comment